CIC
IOVA icon

Cornercap Investment Counsel’s Iovance Biotherapeutics IOVA Stock Holding History

Cornercap Investment Counsel’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-31,360
Closed -$252K – 592
2024
Q2 		$252K Sell
31,360
-297
-0.9% -$3.18K 0.04% 528
2024
Q1 		$469K Hold
31,657
– – 0.07% 471
2023
Q4 		$257K Sell
31,657
-57
-0.2% -$298 0.04% 500
2023
Q3 		$144K Sell
31,714
-450
-1% -$2.94K 0.03% 518
2023
Q2 		$226K Sell
32,164
-5,519
-15% -$39.5K 0.04% 493
2023
Q1 		$230K Hold
37,683
– – 0.04% 487
2022
Q4 		$241K Buy
37,683
+19,925
+112% +$156K 0.04% 492
2022
Q3 		$170K Buy
17,758
+6,145
+53% +$70.9K 0.03% 507
2022
Q2 		$128K Buy
+11,613
New +$152K 0.02% 518

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Cornercap Investment Counsel's IOVA Position: Q3 2024 in Review

Cornercap Investment Counsel sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 31,360 shares — an estimated $252K sold.

Cornercap Investment Counsel first reported a position in IOVA in Q2 2022 and held it in 9 quarters. The position peaked at $469K in Q1 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Cornercap Investment Counsel reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 31,360 Iovance Biotherapeutics shares in Q3 2024, an estimated $252K.
  • Cornercap Investment Counsel first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 9 quarters.
  • Cornercap Investment Counsel's Iovance Biotherapeutics position peaked at $469K in Q1 2024.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Cornercap Investment Counsel's 13F filing for Q3 2024, filed 6 Nov 2024.